清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

医学 红细胞生成 中期分析 艾博汀阿尔法 骨髓增生异常综合症 贫血 国际预后积分系统 补血的 阿尔法 促红细胞生成素 临床试验 内科学 外科 骨髓
作者
Uwe Platzbecker,Matteo Giovanni Della Porta,Valeria Santini,Amer Methqal Zeidan,Rami S. Komrokji,Jake Shortt,David Valcárcel,Anna T Jonasova,Sophie Dimicoli,Ing Soo Tiong,Chien‐Chin Lin,Jiahui Li,Jennie Zhang,Ana Carolina Giuseppi,Sandra Kreitz,Veronika Pozharskaya,Karen L. Keeperman,Shelonitda Rose,Jeevan K. Shetty,Sheida Hayati
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10399): 373-385 被引量:179
标识
DOI:10.1016/s0140-6736(23)00874-7
摘要

Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but responses are limited and transient. Luspatercept promotes late-stage erythroid maturation and has shown durable clinical efficacy in patients with lower-risk myelodysplastic syndromes. In this study, we report the results of a prespecified interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-risk myelodysplastic syndromes in the phase 3 COMMANDS trial.The phase 3, open-label, randomised controlled COMMANDS trial is being conducted at 142 sites in 26 countries. Eligible patients were aged 18 years or older, had a diagnosis of myelodysplastic syndromes of very low risk, low risk, or intermediate risk (per the Revised International Prognostic Scoring System), were ESA-naive, and required red blood cell transfusions (2-6 packed red blood cell units per 8 weeks for ≥8 weeks immediately before randomisation). Integrated response technology was used to randomly assign patients (1:1, block size 4) to luspatercept or epoetin alfa, stratified by baseline red blood cell transfusion burden (<4 units per 8 weeks vs ≥4 units per 8 weeks), endogenous serum erythropoietin concentration (≤200 U/L vs >200 to <500 U/L), and ring sideroblast status (positive vs negative). Luspatercept was administered subcutaneously once every 3 weeks starting at 1·0 mg/kg body weight with possible titration up to 1·75 mg/kg. Epoetin alfa was administered subcutaneously once a week starting at 450 IU/kg body weight with possible titration up to 1050 IU/kg (maximum permitted total dose of 80 000 IU). The primary endpoint was red blood cell transfusion independence for at least 12 weeks with a concurrent mean haemoglobin increase of at least 1·5 g/dL (weeks 1-24), assessed in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study treatment. The COMMANDS trial was registered with ClinicalTrials.gov, NCT03682536 (active, not recruiting).Between Jan 2, 2019 and Aug 31, 2022, 356 patients were randomly assigned to receive luspatercept (178 patients) or epoetin alfa (178 patients), comprising 198 (56%) men and 158 (44%) women (median age 74 years [IQR 69-80]). The interim efficacy analysis was done for 301 patients (147 in the luspatercept group and 154 in the epoetin alfa group) who completed 24 weeks of treatment or discontinued earlier. 86 (59%) of 147 patients in the luspatercept group and 48 (31%) of 154 patients in the epoetin alfa group reached the primary endpoint (common risk difference on response rate 26·6; 95% CI 15·8-37·4; p<0·0001). Median treatment exposure was longer for patients receiving luspatercept (42 weeks [IQR 20-73]) versus epoetin alfa (27 weeks [19-55]). The most frequently reported grade 3 or 4 treatment-emergent adverse events with luspatercept (≥3% patients) were hypertension, anaemia, dyspnoea, neutropenia, thrombocytopenia, pneumonia, COVID-19, myelodysplastic syndromes, and syncope; and with epoetin alfa were anaemia, pneumonia, neutropenia, hypertension, iron overload, COVID-19 pneumonia, and myelodysplastic syndromes. The most common suspected treatment-related adverse events in the luspatercept group (≥3% patients, with the most common event occurring in 5% patients) were fatigue, asthenia, nausea, dyspnoea, hypertension, and headache; and none (≥3% patients) in the epoetin alfa group. One death after diagnosis of acute myeloid leukaemia was considered to be related to luspatercept treatment (44 days on treatment).In this interim analysis, luspatercept improved the rate at which red blood cell transfusion independence and increased haemoglobin were achieved compared with epoetin alfa in ESA-naive patients with lower-risk myelodysplastic syndromes. Long-term follow-up and additional data will be needed to confirm these results and further refine findings in other subgroups of patients with lower-risk myelodysplastic syndromes, including non-mutated SF3B1 or ring sideroblast-negative subgroups.Celgene and Acceleron Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阔达的芹菜完成签到,获得积分10
1秒前
情怀的应助被amiee采纳,获得10
1秒前
Akim的应助被俊逸代男采纳,获得10
1秒前
Qinzhiyuan1990完成签到 ,获得积分10
5秒前
兴奋巧凡完成签到,获得积分10
7秒前
阿浮完成签到 ,获得积分10
8秒前
南风完成签到 ,获得积分10
15秒前
月亮的喵完成签到 ,获得积分20
22秒前
23秒前
俊逸代男发布了新的文献求助10
27秒前
鲜艳的雪曼完成签到,获得积分10
32秒前
A12345678完成签到,获得积分10
32秒前
Edward完成签到,获得积分10
34秒前
张秀伟完成签到,获得积分10
34秒前
lzm完成签到 ,获得积分10
36秒前
LIQIANG完成签到 ,获得积分10
44秒前
Murphy完成签到 ,获得积分10
45秒前
iman完成签到,获得积分10
1分钟前
狂野不乐完成签到,获得积分10
1分钟前
Aboo完成签到,获得积分10
1分钟前
温一完成签到 ,获得积分10
1分钟前
besatified的应助被lovelife采纳,获得10
1分钟前
liu95完成签到 ,获得积分0
1分钟前
从容的水壶完成签到 ,获得积分10
1分钟前
痴情的又亦完成签到,获得积分10
1分钟前
苗苗会喵喵完成签到,获得积分10
1分钟前
冷傲的妙竹完成签到,获得积分10
1分钟前
AmyHu完成签到,获得积分10
1分钟前
小狮子完成签到 ,获得积分10
1分钟前
Ray完成签到 ,获得积分10
2分钟前
白白不喽完成签到 ,获得积分10
2分钟前
Anoxra完成签到 ,获得积分10
2分钟前
独特问梅完成签到,获得积分10
2分钟前
李煜琛完成签到 ,获得积分10
2分钟前
沈惠映完成签到 ,获得积分0
2分钟前
欢呼的访文完成签到,获得积分10
2分钟前
n01W97的应助被科研通管家采纳,获得20
2分钟前
sunflower完成签到,获得积分0
2分钟前
seeyou14完成签到,获得积分0
2分钟前
宝贝的鱼完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185483
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783085
什么是DOI,文献DOI怎么找? 3434576
关于科研通互助平台的介绍 2558929
邀请新用户注册赠送积分活动 2481346